Court Rules on Medicare Drug Price Negotiations for Seniors
TL/DR –
The U.S. Court of Appeals for the Fifth Circuit has upheld the Medicare drug price negotiation program, rejecting a lawsuit from the Pharmaceutical Research and Manufacturers of America (PhRMA) arguing the program’s unconstitutionality. The program, created under the Inflation Reduction Act, allows Medicare to negotiate the prices of high-cost prescription drugs, aiming to reduce costs for beneficiaries and taxpayers. Prescription drug costs remain a significant financial concern for older Americans, and while the pharmaceutical industry argues the program could discourage innovation, many deem the policy essential to combat rising drug prices.
“`html
Fifth Circuit Court Upholds Key Provisions of Inflation Reduction Act
The U.S. Court of Appeals for the Fifth Circuit has upheld significant provisions of the Inflation Reduction Act (IRA), providing yet another setback for the pharmaceutical industry’s attempts to halt Medicare’s drug price negotiation program. This decision refutes a lawsuit brought forward by the Pharmaceutical Research and Manufacturers of America (PhRMA), who questioned the constitutional validity of the Medicare drug price negotiations.
This ruling substantiates the federal government’s stance and marks another courtroom loss for drug manufacturers seeking to stop the program, which empowers Medicare to negotiate the prices of specific high-cost prescription medications used by seniors.
Implications of the Court Decision
As one of the largest financial worries for older Americans, prescription drug costs are a significant concern. The Medicare Drug Price Negotiation Program, established under the Inflation Reduction Act of 2022, aims to decrease costs for beneficiaries and taxpayers by enabling the government to negotiate prices directly with drug manufacturers.
Pharmaceutical industry representatives argue that the program exerts unfair pressure on companies to accept government-set prices, potentially discouraging future innovation. However, many policymakers and beneficiaries believe that the policy is necessary to tackle decades of escalating prescription drug costs.
Details of the Court Ruling
On Wednesday, the Fifth Circuit upheld a previous court decision, dismissing arguments made by PhRMA, the National Infusion Center Association, and the Global Colon Cancer Association. The plaintiffs argued that the Medicare negotiation program violated constitutional protections, including due process guarantees and constraints on government power.
Judge Leslie Southwick, authoring the court’s opinion, stated that drug manufacturers do not have a protected right to sell medicines to Medicare beneficiaries at prices of their choosing. The argument is based on the fact that participation in Medicare and Medicaid is voluntary.
The judgment is in line with similar losses for other industry company challengers, like Merck and AstraZeneca, and lawsuits backed by the U.S. Chamber of Commerce. The U.S. Supreme Court rejected several challenges to the program earlier this year.
Significance of the Ruling
Alex Beene, a financial literacy instructor at the University of Tennessee at Martin, told Newsweek that the ruling is crucial in eliminating another potential legal hurdle to Medicare negotiating lower prices for some of the program’s most expensive prescription drugs. This makes it probable that negotiated pricing will stay a part of Medicare in the future.
Impact on Seniors
For Medicare beneficiaries, the ruling means the drug price negotiation program will continue to operate while legal challenges are ongoing. The program aims to decrease the cost of high-spending prescription drugs covered by Medicare, potentially reducing out-of-pocket expenses for many seniors.
As Michael Ryan, a finance expert and founder of MichaelRyanMoney.com, told Newsweek, “Lower prices can’t guarantee better health, but they can remove one very real barrier to taking medication as prescribed.”
What’s Next?
PhRMA said it is reviewing the Fifth Circuit’s decision and weighing its options. While the organization may appeal to the Supreme Court, the latest decision adds to a growing list of judicial victories for the government.
“`
—
Read More US Economic News